Guidelines for Experiments using Antisense Oligonucleotides and Double-Stranded RNAs
Presenter: David Corey PhD, University of Texas, USA
Date: 6 December 2018
Description: After decades of research and development, synthetic nucleic acids are beginning to enjoy significant success in the clinic. Approved drugs have increased interest in the field and many basic research studies have focused on synthetic nucleic acids that are intended to control the action of mRNA and non-coding RNAs. Unfortunately, the experimental design is often inadequate, leading to misleading results and unconvincing work that does little to advance the field. The goal of this commentary is to outline the problem facing researchers and describe the minimum steps necessary to build a case that observed effects are probably due to interactions at the intended target. A common set of standards for preparing and judging experiments should facilitate interpretation of the strengths and weaknesses of published results.
Recording of the webinar: Click play to view
- Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides.
Stein CA, Krieg AM.
Antisense Res Dev. 1994 Summer;4(2):67-9.
- Proof of mechanism of antisense drugs.
Antisense Nucleic Acid Drug Dev. 1996 Summer;6(2):145-7.
- Keeping the biotechnology of antisense in context.
Nat Biotechnol. 1999 Mar;17(3):209.
- Evaluating the mechanism of action of antiproliferative antisense drugs.
Antisense Nucleic Acid Drug Dev. 2000 Apr;10(2):123-6
- Whither RNAi?
Nat Cell Biol. 2003 Jun;5(6):489-90.
David Corey grew up in Cambridge, Massachusetts. He received his B.A. degree in chemistry from Harvard University and his Ph.D. degree in chemistry from the University of California Berkeley, working under the supervision of Dr. Peter Schultz to develop sequence specific engineering nucleases.
He did postdoctoral work in the laboratory of Dr. Charles Craik at the University of California, San Francisco, where he studied protein engineering and protease function.
Dr. Corey joined the UT Southwestern Pharmacology Department in 1992. He was promoted to Associate Professor with tenure in 1998 and Full Professor in 2003. In 2014, he was named the Rusty Kelley Professor of Medical Sciences. He is also a member of the Department of Biochemistry and the Simmons Cancer Center.
Dr. Corey is an Executive Editor for Nucleic Acids Research and is on the Editorial Board of Cancer Research, Molecular Therapy Nucleic Acids, and Oligonucleotide Therapeutics. He is the author of more than 147 papers and has received funding from the Welch Foundation, NIH, the McKnight Award for Neuroscience Research, the American Heart Association, the Cure Huntington Disease Initiative, and the Friedreich’s Ataxia Association.